Seizert Capital Partners LLC Increases Position in Johnson & Johnson (NYSE:JNJ)

Seizert Capital Partners LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 245,155 shares of the company’s stock after purchasing an additional 3,385 shares during the period. Johnson & Johnson accounts for approximately 1.9% of Seizert Capital Partners LLC’s portfolio, making the stock its 24th largest position. Seizert Capital Partners LLC’s holdings in Johnson & Johnson were worth $40,657,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JNJ. Conquis Financial LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth about $33,000. Bernard Wealth Management Corp. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $36,000. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares in the last quarter. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Capital A Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $50,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $168.03 on Wednesday. The company has a market capitalization of $404.29 billion, a PE ratio of 17.97, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business’s fifty day moving average is $156.65 and its 200 day moving average is $156.22. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.82 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.09%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 17th. Guggenheim reaffirmed a “neutral” rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.